Management admits the market is 'primarily price-driven on our customer side' while pitching an AI premium thesis.
Thesis: Merck KGaA is a price-taker in a market of price-makers. They supply materials to fabs (TSMC, Samsung) who ruthlessly compress supplier margins to protect their own. The 'AI' narrative is largely noise; they don't control the bottleneck (CoWoS/HBM), they just sell the fluids. With Electronics EBITDA margins compressing to 21.8% despite 'leading edge' claims, the structural leverage is missing. You're buying a cyclical recovery in commodity chemicals, not an AI compounder.
Verdict: AVOID — Conviction: MEDIUM
Catalyst: Q1 2024 order intake. Management claims 'solid start' in Jan/Feb. If book-to-bill doesn't firmly cross 1.0, the H2 recovery narrative breaks.
Key Risk: China macro. Life Science exposure is <10%, but global semi material demand is heavily China-weighted. 'Muted environment' comment suggests unquantified downside.
The Tell: Kai Beckmann's admission on the semi market: 'The current market development is primarily price-driven on our customer side.' He explicitly confirms they are waiting for customers to turn price into volume. They are the tail, not the dog.
Friction Level: MODERATE_FRICTION — Timing of the semi cycle inflection. Bulls see early H2 2024 based on 'market data'; Bears see structural commoditization and lack of backlog visibility.
Report not found
The report data is no longer available. Please return to the archive.